Document is current
Any future updates will be listed below
-
Authors
Rueda Domínguez, Antonio https://orcid.org/0000-0001-5890-0149
Cirauqui, Beatriz
García Castaño, Almudena
Alvarez Cabellos, Ruth
Carral Maseda, Alberto
Castelo Fernández, Beatriz
Iglesias Rey, Leticia
Rubió‑Casadevall, Jordi
Arrazubi, Virginia
Mesía, Ricard
-
Funding
Funding for this research was provided by:
Sociedad Española de Oncología Médica
- License Information
-
More Information
Article History
Received: 19 January 2026
Accepted: 21 January 2026
First Online: 17 February 2026
Declarations
:
: Antonio Rueda Domínguez has received speaker fees and attended advisory boards for BMS, MSD, Merck, Roche, and Takeda; and has attended an advisory board for Gilead. Beatriz Cirauqui has received speaker fees and attended an advisory board for BMS, MSD, Merck, and Leo Pharma; and has received other fees from BMS, MSD, and Merck. Leticia Iglesias Rey has received speaker fees from Novartis, Roche, and Pfizer; and has received speaker fees and attended an advisory board for BMS. Virginia Arrazubi has attended an advisory boards for BMS and MSD; has received speaker fees from Organon, Astellas, AstraZeneca, BiOne, MSD; and has received non-financial support from Merck. Ricard Mesía has received speaker fees and attended advisory boards for Merck and MSD; has attended an advisory boards for Bayer, Roche, Nanobiotix, and Seagen; and has received speaker fees from BMS. Almudena García Castaño, Ruth Alvarez Cabellos, Alberto Carral Maseda, Beatriz Castelo Fernández, and Jordi Rubió‑Casadevall have nothing to disclose.
: Not applicable. The manuscript does not contain clinical studies or patient data.
